Table 2.
Comparison of the clinical characteristics of the two groups.
| Group A |
Group B |
|||||||
|---|---|---|---|---|---|---|---|---|
| Type of test | Baseline | 4-Week visit | p Value (1) | Baseline | 4-Week visit | p Value (1) | p Value (2) | p Value (3) |
| OSDI score | 43.58 ± 16.96 | 31.92 ± 15.21 | <0.001 | 39.51 ± 15.77 | 29.97 ± 16.18 | <0.001 | 0.339 | 0.440 |
| TBUT (sec) | 7 ± 2.2 | 7.64 ± 2.60 | 0.027 | 7.15 ± 2.25 | 8.09 ± 2.74 | 0.013 | 0.640 | 0.497 |
| Conjunctival score | 6.67 ± 2.88 | 5.53 ± 2.27 | <0.001 | 7.34 ± 2.20 | 5.09 ± 1.67 | <0.001 | 0.334 | 0.822 |
| Corneal score | 1.23 ± 1.33 | 0.49 ± 0.78 | <0.001 | 1.15 ± 1.07 | 0.44 ± 0.57 | <0.001 | 0.807 | 0.793 |
| Schirmer test (mm) | 6.04 ± 5.25 | 6.56 ± 5.46 | 0.129 | 6.64 ± 6.12 | 7.10 ± 6.40 | 0.115 | 0.676 | 0.441 |
OSDI: Ocular Surface Disease Index questionnaire; TBUT: tear break up time; Group A: patients assigned to use of the product of Tear Natural® single dose eye drops; Group B: patients assigned to use of product of Tearlose® multidose eye drops.
p Value (1): indicates the significant level of paired t-test within A or B groups between baseline and four weeks after intervention.
p Value (2): indicates the significant level of independent t-test for comparing between A and B groups before intervention.
p Value (3): indicates the significant level of independent t test for comparing between A and B groups after four weeks.